FY2029 Earnings Estimate for ATOS Issued By HC Wainwright

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – HC Wainwright issued their FY2029 EPS estimates for shares of Atossa Therapeutics in a report issued on Thursday, January 30th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.14) per share for the year. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share.

Several other research firms have also commented on ATOS. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Ascendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Trading Down 0.0 %

Shares of ATOS opened at $0.85 on Monday. The firm’s 50-day moving average price is $1.02 and its 200-day moving average price is $1.26. The firm has a market capitalization of $106.53 million, a price-to-earnings ratio of -3.85 and a beta of 1.24. Atossa Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.31.

Institutional Investors Weigh In On Atossa Therapeutics

Several hedge funds have recently bought and sold shares of ATOS. Intech Investment Management LLC bought a new position in shares of Atossa Therapeutics in the third quarter worth approximately $29,000. SG Americas Securities LLC lifted its stake in shares of Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Atossa Therapeutics in the third quarter worth approximately $75,000. XTX Topco Ltd lifted its stake in shares of Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after buying an additional 24,951 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Atossa Therapeutics by 177.1% in the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after buying an additional 95,643 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.